PALVELLA THERAPEUTICS, INC. 8K

Palvella Therapeutics reported Q2 2026 results, advanced a rolling NDA and multiple QTORIN clinical programs, strengthened IP, added a new director, completed a Nasdaq Global Market uplisting, and ended the quarter with $250.6 million in cash and investments alongside higher operating losses.

Palvella Therapeutics, Inc. reported its second quarter 2026 financial results and provided a corporate update, highlighting submission of the first module of its rolling NDA to the FDA for QTORIN rapamycin for microcystic lymphatic malformations (with full NDA completion targeted for the second half of 2026 and a potential standalone U.S. launch in the first half of 2027 if approved), advancement and planned initiation timelines for additional QTORIN programs (Phase 3 in cutaneous venous malformations, Phase 2 in disseminated superficial actinic porokeratosis, and ongoing Phase 2 LOTU trial in angiokeratomas), strengthening of DSAP-related IP via a newly issued U.S. patent, expansion plans for the QTORIN platform, corporate developments including the appointment of Matt Pauls to the Board and uplisting to the Nasdaq Global Market, and financial metrics showing $250.6 million in cash, cash equivalents and short-term investments as of June 30, 2026 and a quarterly net loss of $21.9 million driven by increased R&D and G&A expenses.

Filing Facts

CIK

1583648

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-331556

Alert Tier

6